

**Amendments to the Claims**

Please cancel claim 75 without prejudice. A listing of the claims now pending appears below.

**Listing of Claims**

60. (Previously presented) A peptide 15-30 amino acids in length, comprising at least 15 contiguous amino acids of SEQ ID NO:4, wherein the tyrosine residues at amino acids 19-21 must be present.
61. (Previously presented) The peptide of claim 60, wherein one or more tyrosines in said peptide are sulfated.
62. (Previously presented) The peptide of claim 60, wherein the tyrosine at position 12 of SEQ ID NO:4 is present in said peptide.
63. (Previously presented) The peptide of claim 62, wherein one or more tyrosines at positions 12, 19, 20 or 21 are sulfated.
64. (Previously presented) The peptide of claim 63, wherein at least two tyrosines at positions 12, 19, 20 or 21 are sulfated.
65. (Previously presented) The peptide of claim 63, wherein at least three tyrosines at positions 12, 19, 20 or 21 are sulfated.
66. (Previously presented) The peptide of claim 60, wherein said peptide consists of the amino acid sequence of SEQ ID NO:4, and wherein at least one of the tyrosines at positions 19, 20 or 21 of SEQ ID NO:4 are sulfated.
67. (Previously presented) The peptide of claim 60, wherein said peptide is part of a fusion protein in which said peptide is joined to a sequence that inhibits the interaction between HIV and the CD4 receptor.

68. (Previously presented) The peptide of claim 67, wherein said sequence that inhibits the interaction between HIV and the CD4 receptor is either a virus-binding peptide derived from the CD4 receptor or an antibody blocking CD4/virus binding.
69. (Previously presented) The peptide of claim 67, wherein one or more tyrosines in said peptide are sulfated.
70. (Previously presented) The peptide of claim 67, wherein the tyrosine at position 12 of SEQ ID NO:4 is present in said peptide.
71. (Previously presented) The peptide of claim 70, wherein one or more tyrosines at positions 12, 19, 20 or 21 are sulfated.
72. (Previously presented) The peptide of claim 70, wherein at least two tyrosines at positions 12, 19, 20 or 21 are sulfated.
73. (Previously presented) The peptide of claim 70, wherein at least three tyrosines at positions 12, 19, 20 or 21 are sulfated.
74. (Previously presented) The peptide of any one of claims 60-73, wherein said peptide reduces the uptake of an R5 HIV isolate by cultured CCR5-positive immune cells by at least 50% at a concentration of 1  $\mu$ g/ml.
75. (Cancelled)